カンジダ血流感染症に対するミカファンギンの投与量と有効性に関する検討  [in Japanese] Relationship between the Effectiveness and Dose of Micafungin in the Treatment of Candidemia  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

  The Guidelines for Management of Deep-seated Mycoses 2007 recommend the use of micafungin as a first-line agent for the treatment of candidemia. On the package insert, the recommended dose of micafungin is 50 mg/d. However, the Guidelines recommend a micafungin dose of 100-150 mg/d. In the present study, we evaluated the relationship between the effectiveness and dose of micafungin in 42 patients with candidemia who underwent treatment with micafungin. We found that the efficacy rate of micafungin at a dose of 50 mg/d was 40%, whereas that at ≥100 mg/d was 87.5%. Moreover, the treatment was more effective in patients who received ≥100 mg/d of micafungin as compared to those who received 50 mg/d of micafungin. Furthermore, we assessed the efficacy of micafungin according to the <i>Candida</i> species. Among all patients, the efficacy rate of micafungin was found to be lower in patients infected by <i>Candida parapsilosis</i> as compared to those infected by other <i>Candida</i> species. However, among the patients who received ≥100 mg/d of micafungin, the efficacy rate in patients infected by <i>Candida parapsilosis</i> was equivalent to that of patients who were infected by other <i>Candida</i> species. Thus, based on the results of the present study, the optimal micafungin dose for the treatment of candidemia appears to range from 100 to 150 mg/d, as recommended by the Guidelines.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 134(3), 433-438, 2014

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130003391185
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    JPN
  • ISSN
    0031-6903
  • NDL Article ID
    025300893
  • NDL Call No.
    Z19-411
  • Data Source
    NDL  J-STAGE 
Page Top